Direct oral anticoagulants
166 results
109 - 166
Aortic stenosis 
ACCP guidelines for antithrombotics in atrial fibrillation
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
- Deep vein thrombosis
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Older patients with atrial fibrillation treated with DOACs have fewer strokes and systemic emboli than those treated with vitamin K antagonists
- Benefits and harms with oral anticoagulation for atrial fibrillation in patients with history of intracranial hemorrhage (COCROACH)
- Superficial venous thrombophlebitis
- Nephrotic syndrome
- Rivaroxaban is noninferior to warfarin for valvular atrial fibrillation; also associated with fewer strokes
- Mitral regurgitation
- Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Heart valve operation: patient follow-up and complications
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Edoxaban as effective as LMWH for treatment of cancer-associated VTE
- Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Abelacimab has fewer bleeds than rivaroxaban, but study has several important biases
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Vitamin K for improved anticoagulation control in patients receiving warfarin
- Extended rivaroxaban prophylaxis following a medical inpatient stay does not provide a net benefit (MARINER)
- A new bleeding risk score predicts major bleeding better than other scores in elderly patients who take DOACs
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease
- ACG guideline on managing acute lower gastrointestinal bleeding
- Optimal treatment of acute venous thromboembolism
- Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
- Assessment and treatment of a patient with bleeding diathesis
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- Prevention of venous thromboembolism
- Systemic lupus erythematosus (SLE)
- Electrical cardioversion
- Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults: Cochrane systematic review
- Home versus in‐patient treatment for deep vein thrombosis
- Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
- Lumbar puncture
- Management of acute atrial fibrillation
- Acute coronary syndrome
- Cerebral infarction (ischaemic stroke)
- COVID-19 and other coronavirus infections